Clinical Trial Results: A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial assessing long-term efficacy, safety, and tolerability of repeated upadacitinib (ABT-494) in Crohn's disease; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Crohn's Disease (CD) | Phase 2 | Status: COMPLETED | Results posted: 2026-08-13